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that the genetic variants of TCF7L2 may predispose the carriers to the incidence of T2DM, β-cell dysfunctions/ insulin in sufficiency. In order to understand the prevalence and influence of TCF7L2 polymorphisms in T2DM in the south Indian population, we had earlier brought to focus that TCF7L2 gene variants are prevalent, incident in the T2DM patients, non-diabetic participants in the south Tamil Nadu population (Ramanathan B et al., Int J Community Med Public Health 2019 Mar; 6 (3):1025-1030). In sequence, the present study aims to further understand the impact of the TCF7L2 gene variants on the age onset of T2DM, and the pancreatic insulin synthesis/secretion efficiency by analyzing if the TCF7L2 rs7903146, rs12255372 carriers of the regional population presented an association with earlier T2DM incidence, early insulin dependency. The results from our study primarily reveal that the T2DM carriers of the TCF7L2 SNPs present an early onset of T2DM, early dependence on insulin therapy and that screening for TCF7L2 rs7903146, rs12255372 will significantly aid disease management, enable well-being in T2DM patients.
methoDs
The present study was carried out in Alpha Health Foundation, Alpha Hospital and Research Center. The proposed study group T2DM patients were enrolled for the study on clearance from the Institutional Ethical Committee (IEC) and upon informed consent from the participants. A total of 90 T2DM patients participated in the present study and they were categorized under three groups. Group A T2DM patients presented with a T2DM onset ≤40 years and had less than 10 years of T2DM onset; Group B T2DM patients presented with T2DM onset ≤ 40 years, had greater than 10 years of T2DM onset and are insulin dependent; group C T2DM patients had greater than 10 years of T2DM onset and were insulin independent. Details pertaining to the patients' age, height, weight, age of T2DM onset, duration of diabetes, medication history, history of comorbidities, and the age at which insulin therapy was initiated and other therapeutic interventions were obtained.
Routine clinical assessments including anthropometric measurements and biochemical tests relevant to glucose, lipid metabolism were carried out according to standard protocols. Genomic DNA was extracted from peripheral blood samples using a QIAamp DNA Blood Mini Kit (QIAGEN India Pvt. Ltd, New Delhi, India) according to the manufacturer's protocol. Quantitative and qualitative (260/280 nm absorbance ratio) assessment of the DNA samples were carried out using a nanodrop, Thermo scientific, India.
Determination of the presence of the TCF7L2 polymorphism rs7903146 was carried out by PCR amplification of a region corresponding to a 318bp product using the forward primer 5'-GGTAATGCAGATGTGATGAGATCT-3', and the reverse primer 5'-AGATGAAATGTAGCAGTGAAGTGC-3'. The PCR conditions pertained to an initial denaturation of 3 min at 94°C followed by 32 cycles of denaturation for 1 min at 94°C, annealing for 1 min at 58°C and extension for 1 min at 72°C and final extension of 5 min at 72°C. A 352bp PCR product encompassing the region pertaining to the rs12255372 SNP was obtained using PCR with the conditions pertaining to the initial denaturation of 5 min at 94°C, followed by 30 cycles of denaturation for 1 min at 94°C, annealing for 30 sec at 52°C and elongation for 1 min at 72°C, with a final elongation of 5 min at 72°C, using the forward primer 5'-TTTTGTTAATGGCTTGCAGGT-3', and the reverse primer 5'-GCGCATGCTAATTTCCTGTC-3'. Allele specific PCR (T allele) was also carried out for the TCF7L2 polymorphism rs12255372 (256bp) using the forward primer 5'-TTTTGTTAATGGCTTGCAGGT-3' and 5'-GGCCTGAGTAATTATCAGAATATGATA-3' reverse primer (conditions corresponded to initial denaturation of 5 min at 94°C, followed by 30 cycles of 1 min denaturation at 94°C, 30 secs annealing at 60°C, 1 min primer extension at 72°C and final extension of 5 min at 72°C).
The PCR products were visualized after electrophoresis using a UV gel documentation system (Medicare, Chennai, India) and further gel extracted, purified and utilized for direct sequencing (Agrigenome, Kochi, Kerala).
Statistical analysis
All statistical analysis were carried out using SPSS version 20.0 for Windows (IBM Chicago, IL, USA) and Graph Pad Prism version 7.04 for Windows (Graph Pad Software, La Jolla California USA).
resuLts
Recent years have seen a surge in global molecular genetic studies that aim to understand the prevalence, influence of TCF7L2 polymorphisms as they predict the risk of incidence of T2DM in the individuals. Our earlier pilot studies had revealed that a considerable number of T2DM patients and healthy volunteers in the regional population of south Tamil Nadu, presented the TCF7L2 rs7903146, rs12255372 SNPs. Therefore we further aimed to elucidate the impact of these polymorphisms in the T2DM course by means of studying the prevalence, impact of these SNPs in T2DM patients, and determining if the carriers of TCF7L2 SNPs were more likely to require insulin therapy at earlier stages.
The overall mean age, BMI, HbA1c levels, triglyceride levels and the total cholesterol levels in the patients of the study groups are presented in Table 1 . As indicated We then assessed the genotypic distribution for rs7903146, rs12255372 in the group A, group B and group C patients. Figure 1 depicts the results that are representative for the rs7903146 PCR amplification, direct sequencing. Figure 1a presents a representative image of the PCR amplified 318bp product which encompasses the genomic region pertaining to the rs7903146 SNP and Figure 1b -d are representative images for the genotypic information. Figure 1b presents the chromatogram image for wild type carriers indicating in the sequencing outputs are represented in Figure 2c and d and correspond to sequencing chromatogram images of a wild type carrier GC (Forward, reverse strands) and a heterozygous carrier (GA in the forward and reverse strands respectively). Together, the results obtained demonstrate the reliability and feasibility of the utilization of PCR based strategies, PCR product sequencing in the identification of the rs7903146, rs12255372 in molecular diagnosis.
Based on the genotype prevalence data presented in Table 2 , it can be observed that group A presented with a maximum percentage of (74.3%) patients who were positive for the rs7903146, rs12255372 (48.6%) SNPs. It can also be observed that the early onset insulin dependent group B comprised of 63.6% patients positive for rs7903146 and 31.8% positive for rs12255372. The group C non insulin dependent patients a CG allelic distribution in the forward and reverse sequences. Similarly Figure 1c and d presents the genotype of a heterozygous carrier (CA), homozygous carrier (TA) in the aligned forward and reverse sequences respectively. Figure 2a presents the 352bp PCR product that encloses the genomic region pertaining to the rs12255372 polymorphism and Figure 2b presents a representative image for the allele specific PCR results that enable identification of the presence of SNP. As indicated in the image L1 and L2 are negative and positive control samples that are represent by the absence and presence of the 256 bp rs12255372 SNP containing region. ASP results for patients presenting the rs12255372 GT/TT alleles are represented in L5, L6 and L11 of the image, thus indicating that ASP can easily and routinely be utilized for the determination of the rs12255372 TCF7L2 SNP. Further presented with the maximum percentage of wild type carriers (51.7%) for rs7903146 and group B presented with a higher percentage of patients negative (68.2%, GG) for the rs12255372 SNP. Further analysis of the anthropometric and clinical parameters in the rs7903146, rs12255372 wild type and hetero/homozygous carriers are presented in Table 3 . Association analysis for determining the influence of the SNPs in age, age onset for incidence of T2DM, BMI and parameters associated with glucose, lipid metabolism between the groups and amidst the same groups, in carriers and non-carriers revealed significant differences in total cholesterol levels between group A and group C for the rs7903146 SNP (CC Vs CT/TT genotype; P = 0.027).
We next proceeded to analyze the impact of the TCF7L2 polymorphisms rs7903146, rs12255372 on the age at which T2DM incidents, and insulin dependency begins based on gender categorization in the study group patients. As indicated in Figure 3a , amidst the assessed population, the TCF7L2 SNP positive female T2DM patients presented with a significantly lower onset age for T2DM [rs7903146 (P < 0.01), rs12255372 (P < 0.05)]. Detailed analysis in the early onset, insulin dependent group B patients indicated that the rs7903146, rs12255372 carriers presented with a lower age for T2DM incidence and insulin dependency in comparison to the wild type carriers [ Figure 3b ]. Correlation/regression analysis for determining the influence of the SNPs in earlier incidence of T2DM and early insulin dependency reveal that the rs7903146 positive patients exhibited an early dependence on insulin (P = 0.018). The results also indicate that the rs12255372 SNP significantly influences the (P = 0.042) onset age for T2DM in group C patients and the dependence age for insulin therapy in Group B patients (P = 0.026). Taken together, the results from the present study strongly suggest that rs7903146, rs12255372 TCF7L2 carriers present with impaired β-cell efficiency reflecting with an accelerated disease course that requires early dependence on insulin therapy.
DisCussion
Genetic variants from the TCF7L2 gene are strongly associated with T2DM and several studies have demonstrated the influence of rs7903146, rs12255372 with risk of incidence, insulin secretion, β cell efficiency and T2DM obesity. [11, 12] In conjunction with several other reports, including ours, the results of the present study indicates that the percentage prevalence of TCF7L2 polymorphisms in the T2DM patients was significantly high. [13] Earlier research studies addressing the mechanistic impact of TCF7L2 SNPs in detail (insulin synthesis, secretion, glucagon secretion) demonstrated that the TCF7L2 SNP carriers exhibit aberrant insulin dependent outputs. Other subsequent studies have also reported that the TCF7L2 polymorphisms influenced peak insulin response indicating their association with hepatic insulin clearance/processing. [14] Very recent transcriptional network studies have added value to such earlier findings by demonstrating that TCF7L2 regulates pro-insulin production in a genotype dependent manner and that the TCF7L2 SNP carriers present with lower insulin levels, secretion, and thereby mark a relatively aggressive disease course. [15, 16] In a parallel track, interesting clinical studies demonstrate that the rs7903146 SNP carriers presented with impaired absolute, relative insulin secretion, increased peripheral sensitivity, elevated rate of endogenous glucose production, and inadequate insulin levels for compensation of insulin resistance. Based on all of these findings, it can be strongly suggested that screening for the TCF7L2 risk allele carriers, and providing appropriate therapeutic interventions for the TCF7L2 carrier T2DM patients would drastically alleviate the burden associated with the T2DM disease. [17, 18] Moving ahead and owing to the lack of knowledge pertaining to the influence of the TCF7L2 polymorphisms in the T2DM disease course in the regional population, we first examined the association between the TCF7L2 SNP carriers and the T2DM incidence age, the disease course, by means of understanding the patient's need for insulin therapy. In conjunction with prior research studies that have reported an association of rs7903146 SNP with early onset T2DM, [17] the results from the present study also indicate that the TCF7L2 rs7903146 and rs12255372 polymorphisms are significantly associated with T2DM incidence age. Such evidences cumulatively highlight that the TCF7L2 SNP carriers may strongly be predisposed to multiple facets in the incidence, progression of T2DM in the Indian/south Tamil Nadu population. It is further observed from the present study that the TCF7L2 rs7903146, rs12233572 polymorphisms are associated with earlier dependence on insulin when compared to the wild type carriers. Such an observation is in line with findings that have associated the presence of TCF7L2 SNPs with lower insulin levels and inefficient β-cell functions [8, 11, 16] that may resultantly lead to earlier dependence on insulin during the course of T2DM. The current study results thus provide regional evidence for early insulin dependence for the first time, and further draw attention to the fact that T2DM patients with the TCF7L2 polymorphisms may require additional measures to prevent the accelerated disease course. Put together, concurrent detailed and large scale studies are required to introduce life style and therapeutic modulations in the SNP carriers.
ConCLusion
The present TCF7L2 SNP study in the regional south Tamil Nadu population indicates that active screening measures for the TCF7L2 rs7903146, rs12255372 will not only prevent T2DM incidence, but will also introduce appropriate intervention strategies that would effectively control the accelerated disease course in the SNP carriers.
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